In addition, the checkpoint PD-1 inhibitors nivolumab and pembrolizumab as well as the PD-L1 inhibitor atezolizumab are used as second-line treatments for NSCLC [73]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.